Johnson & Johnson said MedTech sales rose 5.4 per cent in 2025 to US$33.8bn.
The group said operational sales in its Innovative Medicine division rose 5.3 per cent year on year to about US$60.4bn.
It said MedTech growth was driven by electrophysiology products, Abiomed in cardiovascular care and wound-closure products in general surgery, alongside the acquisition of Shockwave.
Electrophysiology is the study of the heart’s electrical activity and is used to diagnose and treat abnormal heart rhythms.
Joaquin Duato, chairman and chief executive, said: “Our success over the last year was supported by 15 major launches and more than 40 regulatory approvals in major markets, and with more than 60 active clinical trials, we have significant momentum going into 2026.
Duato said Abiomed delivered operational growth of 18 per cent in the fourth quarter, while Shockwave delivered 23 per cent.
Johnson & Johnson completed its acquisition of Shockwave in May 2024.
Shockwave’s intravascular lithotripsy platform treats coronary artery disease; intravascular lithotripsy uses sound waves to break up calcium deposits in blocked arteries.
The company said at the time it aimed to bring Shockwave’s technology to more patients and lift its annual sales to at least US$1bn.
During 2025, Shockwave and Carvykti each surpassed US$1bn in annual sales for the first time, taking to 28 the number of platforms generating at least that much annual revenue.
Looking ahead, Johnson & Johnson forecast overall worldwide operational sales growth of 5.7 per cent to 6.2 per cent, which could take it past the US$100bn milestone.
It guided to operational sales of US$99.5bn to US$100.5bn.
Duato said Johnson & Johnson will soon become the only healthcare company delivering over US$100bn in revenue.
He said: “How is that possible? It’s possible because we have tremendous strength and depth, both in Innovative Medicine and in MedTech.
“We are different from other companies. We are not focused on one or two growth drivers.”
